Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.